Pneumonia Immunization in Older Adults: Review of Vaccine Effectiveness and Strategies

Overview

Journal Clin Interv Aging

Publisher Dove Medical Press

Specialty Geriatrics

Date 2012 Nov 16

PMID 23152675

Citations 17

Authors

Usama Assaad

Ibrahim El-Masri

Jahan Porhomayon

Ali A El-Solh

Affiliations

Soon will be listed here.

Abstract

Vaccination remains the primary preventive strategy in the elderly against Streptococcus pneumoniae and influenza infections. The effectiveness of this strategy in preventing pneumonia has been in doubt despite the increase in vaccination coverage among older adults. Randomized controlled trials (RCTs) and observational studies aimed at determining clinical outcomes and immune response following pneumococcal vaccination have yielded conflicting results. The protective efficacy of pneumococcal vaccination against pneumonia in older adults has not been firmly established due to a lack of RCTs specifically examining patients ≥ 65 years of age. Similarly, the reported benefits of influenza vaccination have been derived from observational data. The assessment of clinical benefit from influenza vaccination in the elderly population is complicated by varying cohorts, virulence of the influenza strain, and matching of vaccine and circulating viral strains. The presence of selection bias and use of nonspecific end points in these studies make the current evidence inconclusive in terms of overall benefit. The development of more immunogenic vaccines through new formulations or addition of adjuvants holds the promise of revolutionizing delivery and improving efficacy. Dismantling existing barriers through education, providing technology assistance predominantly to developing countries, and establishing clear regulatory guidance on pathways for approval are necessary to ensure timely production and equitable distribution.

Citing Articles

Association Between Pneumococcal Vaccination Uptake and Loneliness Among Regular Patients in Rural Community Hospitals: A Cross-Sectional Study.

Ohta R, Yakabe T, Adachi H, Sano C Cureus. 2024; 16(7):e65293.

PMID: 39184760 PMC: 11343486. DOI: 10.7759/cureus.65293.

Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models.

Usai C, Ainsua-Enrich E, Gales V, Pradenas E, Lorca-Oro C, Tarres-Freixas F NPJ Vaccines. 2024; 9(1):48.

PMID: 38413645 PMC: 10899648. DOI: 10.1038/s41541-024-00840-0.

A broad-spectrum pneumococcal vaccine induces mucosal immunity and protects against lethal challenge.

Chiu F, Tu L, Chen W, Zhou H, Liu B, Liu S Emerg Microbes Infect. 2023; 12(2):2272656.

PMID: 37855122 PMC: 10606790. DOI: 10.1080/22221751.2023.2272656.

Immunogenicity of an AAV-Based COVID-19 Vaccine in Murine Models of Obesity and Aging.

Maciorowski D, Diop C, Bhatt U, Estelien R, Li D, Chauhan R Viruses. 2022; 14(4).

PMID: 35458550 PMC: 9026898. DOI: 10.3390/v14040820.

Multidimensional Frailty and Vaccinations in Older People: A Cross-Sectional Study.

Veronese N, Vassallo G, Armata M, Cilona L, Casalicchio S, Masnata R Vaccines (Basel). 2022; 10(4).

PMID: 35455304 PMC: 9028390. DOI: 10.3390/vaccines10040555.

References

Sankilampi U, Honkanen P, Bloigu A, Herva E, Leinonen M . Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis. 1996; 173(2):387-93. DOI: 10.1093/infdis/173.2.387. View

Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V . Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet. 2005; 366(9492):1165-74. DOI: 10.1016/S0140-6736(05)67339-4. View

Simonsen L, Taylor R, Viboud C, Miller M, Jackson L . Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis. 2007; 7(10):658-66. DOI: 10.1016/S1473-3099(07)70236-0. View

Allsup S, Haycox A, Regan M, Gosney M . Is influenza vaccination cost effective for healthy people between ages 65 and 74 years? A randomised controlled trial. Vaccine. 2004; 23(5):639-45. DOI: 10.1016/j.vaccine.2004.07.008. View

Bernstein D, Edwards K, Dekker C, Belshe R, Talbot H, Graham I . Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis. 2008; 197(5):667-75. DOI: 10.1086/527489. View

Simonsen L, Reichert T, Viboud C, Blackwelder W, Taylor R, Miller M . Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med. 2005; 165(3):265-72. DOI: 10.1001/archinte.165.3.265. View

Hak E, Grobbee D, Sanders E, Verheij T, Bolkenbaas M, Huijts S . Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med. 2008; 66(9):378-83. View

Fiore A, Shay D, Broder K, Iskander J, Uyeki T, Mootrey G . Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep. 2008; 57(RR-7):1-60. View

Ortqvist A . Pneumococcal vaccination: current and future issues. Eur Respir J. 2001; 18(1):184-95. DOI: 10.1183/09031936.01.00084401. View

10.

Johnstone J, Eurich D, Minhas J, Marrie T, Majumdar S . Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia. Clin Infect Dis. 2010; 51(1):15-22. DOI: 10.1086/653114. View

11.

Weaver M, Krieger J, Castorina J, Walls M, Ciske S . Cost-effectiveness of combined outreach for the pneumococcal and influenza vaccines. Arch Intern Med. 2001; 161(1):111-20. DOI: 10.1001/archinte.161.1.111. View

12.

de Diego C, Vila-Corcoles A, Ochoa O, Rodriguez-Blanco T, Salsench E, Hospital I . Effects of annual influenza vaccination on winter mortality in elderly people with chronic heart disease. Eur Heart J. 2008; 30(2):209-16. DOI: 10.1093/eurheartj/ehn498. View

13.

Musher D, Manof S, Liss C, McFetridge R, Marchese R, Bushnell B . Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis. 2010; 201(4):516-24. DOI: 10.1086/649839. View

14.

Kaufman P . Pneumonia in old age; active immunization against pneumonia with pneumonococcus polysaccharide; results of a six year study. Arch Intern Med (Chic). 2010; 79(5):518-31. DOI: 10.1001/archinte.1947.00220110058004. View

15.

Honkanen P, Keistinen T, Miettinen L, Herva E, Sankilampi U, Laara E . Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine. 1999; 17(20-21):2493-500. DOI: 10.1016/s0264-410x(99)00069-9. View

16.

Chu D, Hwang S, Lim F, Oh H, Thongcharoen P, Yang P . Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine. 2009; 27(52):7428-35. DOI: 10.1016/j.vaccine.2009.07.102. View

17.

Alfageme I, Vazquez R, Reyes N, Munoz J, Fernandez A, Hernandez M . Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax. 2005; 61(3):189-95. PMC: 2080738. DOI: 10.1136/thx.2005.043323. View

18.

Nichol K . Challenges in evaluating influenza vaccine effectiveness and the mortality benefits controversy. Vaccine. 2009; 27(45):6305-11. DOI: 10.1016/j.vaccine.2009.07.006. View

19.

Romney M, Hull M, Gustafson R, Sandhu J, Champagne S, Wong T . Large community outbreak of Streptococcus pneumoniae serotype 5 invasive infection in an impoverished, urban population. Clin Infect Dis. 2008; 47(6):768-74. DOI: 10.1086/591128. View

20.

Goodwin K, Viboud C, Simonsen L . Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2005; 24(8):1159-69. DOI: 10.1016/j.vaccine.2005.08.105. View